The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You can't check because none of us can access post history at the moment. But I can assure you that I did indeed post the letter on here ( with all the good bits included).
The thread was entitled, Letter from Maggie Throup via my MP.
And I still think you are an imbecile.
Despite the share price volatility, many investors forget that Avacta owns 2 valuable scientific platforms. The first being it's #Affimer technology that is used to create 1st class immunotherapies, diagnostics & medical purification products.
The 2nd is the pre|CISION platform that already has Prodoxurubin (AVA6000) in phase 1 clinical trials with initial ‘pk’ data due for release shortly.
This morning came further encouraging news that a 2nd lead candidate AVA3996, had been selected with aim of commencing Phase I clinical trials in H2’23.
Indicating to me too that the underlying data so far from the ongoing Prodoxorubicin study is also positive. As otherwise management probably would not have taken this important decision just yet.
Similarly the upside is significant, as AVA3996 - being a FAP-targeted proteasome inhibitor - addresses a market that is expected to be worth $2.3bn by 2026.
CEO Alastair Smith adding: “We are excited by the early pre-clinical data for AVA3996, the 2nd of Avacta's pre|CISION pro-drugs following on from AVA6000."
"The pre|CISION platform has the potential to generate a significant pipeline of safer, better tolerated chemotherapies to treat a wide range of cancers. It represents a major commercial opportunity and the principal value driver for the Group.”
"If AVA3996 is shown to have a significantly improved safety profile. Then not only could it provide a better tolerated treatment for multiple myeloma, but it has the potential to be the first proteasome inhibitor to be suitable for treating solid tumours, thereby significantly increasing the market opportunity."
Sajid Javid acknowledges 'global shortage' of COVID tests
The health secretary spoke to Tory MP Sir Roger Gale in a phone call this afternoon amid reports of a lack of coronavirus tests.
The North Thanet MP said: "The long and the short of it is he says there is a worldwide shortage of lateral flow tests.
"A British company that is making them has ramped up its production line fourfold and we are buying the lot, plus anything we can get from anywhere else around the world, but we are competing in a global market."
He said his constituents had been advised to keep trying online as availability was updated throughout the day.
Sir Roger said the shortage of lateral flow tests was having a knock-on effect with people opting for PCR tests instead, but "there is not enough capacity" in laboratories to process them.
https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired
How many of these signs do you recognise ?
https://www-euronews-com.cdn.ampproject.org/v/s/www.euronews.com/amp/2021/11/29/portugal-has-re-imposed-covid-19-travel-restrictions-could-other-eu-nations-do-the-same?amp_gsa=1&_js_v=a6&usqp=mq331AQIKAGwASCAAgM%3D#amp_tf=From%20%251%24s&aoh=16382649829640&csi=0&referrer=https%3A%2F%2Fwww.google.com&share=https%3A%2F%2Fwww.euronews.com%2F2021%2F11%2F29%2Fportugal-has-re-imposed-covid-19-travel-restrictions-could-other-eu-nations-do-the-same
Don't think it will be too long for the rest of Europe to follow Portugal.
Also snipped from a response from within the government to my ongoing remonstrations.
The performance data that Avacta published on it's AffiDX SARS-CoV-2 antigen lateral flow device (LFD) test looks positive. However, we cannot comment on the validation status of individual LFDs.
A number of UK products have been through Porton Down validation and have passed phase 3a validation. None of these has yet achieved regulatory approval to allow them to be used in the settings we require. However, work is underway to secure regulatory approval for the suppliers of these products, and we hope that this will be completed successfully in the coming months.